Evidence map›Paper›PMID 31181128›Full record

ArticlePloS one2019

Serum albumin and mortality in patients with HIV and end-stage renal failure on peritoneal dialysis.

Kwazi Celani Zwakele Ndlovu, Perpetual Chikobvu, Thabiso Mofokeng, Verena Gounden, Alain Assounga

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. rs1445776009 variants in the humanInternational journal of health sciences
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kwazi Celani Zwakele NdlovuDivision of Nephrology, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0001-5283-2085
Perpetual ChikobvuDepartment of Health of the Free State, Bloemfontein, South Africa.
Thabiso MofokengDepartment of Internal Medicine, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0001-5944-8350
Verena GoundenDepartment of Chemical Pathology, Inkosi Albert Luthuli Hospital, Durban, South Africa.
Alain AssoungaDepartment of Nephrology, University of KwaZulu-Natal, Durban, South Africa.
University of the Free State · ZAUniversity of KwaZulu-Natal · ZA

Funding

ENHANCING, TRAINING, RESEARCH CAPACITY AND EXPERTISE IN HIV CARE-ENTREER24TW008863 · FIC · UNIVERSITY OF KWAZULU-NATAL · PI BOBAT, RAZIYA, HAMMER, SCOTT M · 2010 to 2015
$8.6M
FIC NIH HHS R24 TW008863
6 · The paper itself

Abstract

backgroundPeritoneal dialysis (PD) is an easily implementable dialysis modality in end-stage renal disease (ESRD). PD may improve access to renal replacement therapy in low- and middle-income countries; however, these countries have a higher prevalence of protein-energy wasting in patients and poorer socioeconomic conditions. We evaluated the effects of HIV infection on serum albumin levels in ESRD patients starting continuous ambulatory PD (CAPD) and mortality outcomes.

methodsWe conducted a single-center prospective cohort study of consecutive incident CAPD patients recruited from two hospitals in Durban, South Africa, from September 2012 to February 2015. Seventy HIV-negative and 70 HIV-positive ESRD patients were followed monthly for serum albumin levels and mortality events during the first 18 months of CAPD therapy.

resultsThe HIV-positive cohort recorded 28 deaths (40%) among patients with a functional CAPD catheter at 18 months and 13 deaths (18.6%) in the HIV-negative cohort (p = 0.005). The mean serum albumin levels were lower in the HIV-positive cohort than in the HIV-negative cohort during the 18-month follow-up. The mean difference in serum albumin levels between the two cohorts was 4.24 g/L (95% confidence interval [CI] 2.02-6.46, p<0.001) at baseline and 3.99 g/L (95% CI 1.19-6.79, p = 0.006) at 18 months. HIV-positive status (adjusted regression coefficient -2.84, CI -5.00--0.67, p = 0.011), diabetes (adjusted coefficient -2.85; CI, -5.58--0.12; p = 0.041), and serum C-reactive protein and blood hemoglobin levels were independent predictors of serum albumin levels on multivariable linear regression. Baseline serum albumin <25 g/L (subdistribution-hazard ratio [SHR] 13.06, 95% CI 3.09-55.14, p<0.001) and CD4+ cell count <200 cells/μL (SHR 3.2, CI 1.38-7.45, p = 0.007) were independent predictors of mortality in our competing risk model.

conclusionsHIV infection can adversely affect serum albumin levels in ESRD patients managed with CAPD, while low baseline serum albumin levels and impaired immunity reliably predict mortality.

Indexed as

CD4 Lymphocyte CountC-Reactive ProteinHIV InfectionsHumansKidney Failure, ChronicPeritoneal Dialysis, Continuous AmbulatoryProportional Hazards ModelsProspective StudiesSerum AlbuminSouth AfricaC-Reactive ProteinSerum Albumin

Identifiers

PMID31181128
PMCPMC6557525
OpenAlexW2952982749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.